Clinical trial NCT02851004: Special Combination of BBI608 and Pembrolizumab
Official title: A Phase Ib/II Study of BBI608 in Combination With Pembrolizumab in Patients With Metastatic Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Metastatic Colorectal Cancer
Lead sponsor: National Cancer Center Hospital East
Sponsor class: OTHER
Collaborators: name: Sumitomo Pharma Co., Ltd.
First posted: 2016-08-01
Enrollment: 55
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: \[Phase Ib\] 6 to 9 patients

\[Phase II\] Cohort A (MSI-H): 10 patients Cohort B (MSS): 40 patients Including patients with metastatic CRC treated at the recommended dose (RD) level in the Phase Ib part who meet criteria for the full analysis set (FAS)

\[Additional cohort to the Phase II part\]

1. st stage: CMS 1 or 4, MSS right-side colon cancers\*: 10 patients
2. nd stage:

   1. : If no patient shows a partial or complete response in the 1st stage, the study will be prematurely terminated.
   2. : If 1 or 2 patients show a partial or complete response in the 1st stage, 19 patients with CMS 1 or 4, MSS right-side colon cancers will be enrolled additionally.
   3. : If 3 or more patients show a partial or complete response in the 1st stage, 19 patients with CMS 1 or 4, MSS right-side colon cancers and 10 patients with CMS 1 or 4, MSS left-side colon cancers\* will be enrolled additionally.
Primary purpose: TREATMENT

Brief summary: the efficacy and safety of BBI608 in combination with pembrolizumab

Detailed description: This is a multicenter, open-label Phase Ib/II study to exploratively evaluate the efficacy and safety of BBI608 in combination with pembrolizumab in patients with metastatic colorectal cancer (CRC) not responded to or intolerant of standard chemotherapy.The same analysis will be performed for the additional cohort to the Phase II part, consisting of patients with metastatic CMS 1 or 4, MMS, CRC not responsive to or intolerant of standard chemotherapy.

Eligibility criteria: For the additional cohort to the Phase II part, screening tests will be performed to identify CMS 1 or 4 and MSS before obtaining informed consent.

Patients, who meet all of the following inclusion criteria and none of the exclusion criteria, are eligible for enrollment in the study.

Inclusion Criteria

1. Patients who personally provided written consent to be the subjects of the study
2. Age of 20 years or older on the day of informed consent
3. \[Phase Ib\] Histologically confirmed gastrointestinal cancer

   \[Phase II\] Histologically confirmed colon or rectal cancer that is adenocarcinoma , and identification of at least the KRAS codon 12 and 13 mutation status determined by RAS gene testing. Confirmation of the microsatellite instability (MSI) status.

   \[Additional cohort to the Phase II part\] Histologically confirmed colon or rectal cancer that is adenocarcinoma, and identification of RAS mutation status. Identification of CMS 1 or 4 and MSS by screening tests.
4. \[Phase Ib\] Gastrointestinal cancer not responded to or intolerant of standard chemotherapy

   \[Phase II\]A history of treatment with one or more regimens of the following standard chemotherapies for metastatic CRC, and being not responded to or tolerated the chemotherapies

   \[Additional cohort to the Phase II part\] In accordance with Cohort B in the Phase II part.
5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1
6. Patients with evaluable lesions (Cohort A in Phase II and Phase Ib) or measurable lesions (Cohort B in Phase II and the additional cohort to the Phase II part) specified in the RECIST version 1.1
7. Patients with adequate organ function based on the following laboratory values measured within 7 days before enrollment
8. Women of childbearing potential who are negative in a pregnancy test within 7 days before enrollment. Both male and female patients who consent to practice appropriate contraception during the study and for 4 months after the discontinuation of the protocol treatment
9. Patients with an expected survival of at least 3 months

Exclusion criteria

1. Patients who received chemotherapy, molecular-targeted agents and/or palliative radiotherapy within 2 weeks before the start of the protocol treatment or have not recovered from toxicity caused by previous treatment
2. Patients who underwent general anesthesia, surgery requiring hospitalization and extensive radiotherapy within 4 weeks before the start of the protocol treatment or minor surgery such as implantation of a central venous access device within two weeks before the start of the protocol treatment
3. Patients with active central nervous system metastases or carcinomatous meningitis.
4. Pregnant or lactating women
5. Patients who are unable or not willing to take BBI608 capsules every day
6. Patients with gastrointestinal disease markedly interfering with the absorption of oral formulations as judged by the investigator
7. Patients with active autoimmune disease requiring systemic treatment within 2 years before the start of the protocol treatment.
8. Patients with a history or signs of interstitial lung disease or active non-infectious pneumonitis
9. Patients who underwent organ or bone marrow transplantation
10. Patients who received a live vaccine within 30 days before the start of the protocol treatment
11. Patients who participated in another clinical study within 4 weeks before the start of the protocol treatment and used or using an investigational drug or device
12. Patients who previously received immunotherapy with drugs targeting PD-1, PD-L1 and/or PD-L2 or BBI608 therapy, or took part in a clinical study of pembrolizumab or BBI608
13. Patients with uncontrollable complications
14. Patients with a history of other malignancies within 3 years before the start of the protocol treatment.
15. Patients with clinically significant Electrocardiogram (ECG) abnormalities
16. Patients with a history of Human Immunodeficiency Virus (HIV)
17. Patients with active hepatitis B or C

Primary outcomes:
measure: irORR
timeFrame: 2 years
measure: ORR
timeFrame: 1 year
Secondary outcomes:
measure: irPFS
timeFrame: 12 weeks
measure: ORR
timeFrame: 2 years
measure: irORR
timeFrame: 1 year
measure: Progression free survival rate at week 12 determined by the RECIST version 1.1
timeFrame: 12 weeks
measure: PFS
timeFrame: 3 years
measure: OS
timeFrame: 4 years
measure: DCR
timeFrame: 2 years
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: 4 years
measure: Pharmacokinetic
timeFrame: 2 months
measure: Pharmacokinetic
timeFrame: 2 months
Other outcomes:
measure: efficacy according to immune status - Immune status will be analyzed using biopsy and blood samples by flow cytometry, RNA seq, whole exome sequencing, and immunohistochemistry etc.
timeFrame: 3 years
measure: safety according to immune status
timeFrame: 3 years
Locations:
city: Kashiwa
country: Japan
facility: National Cancer Center Hospital East
state: Chiba
Study officials:
affiliation: National Cancer Center Hospital East
name: Takayuki Yoshino, Dr
role: STUDY_CHAIR
References: